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Background and Purpose  Fibroblast growth factor 23 (FGF23) is associated with athero-
sclerosis via nitric-oxide-associated endothelial dysfunction and calcium-phosphate-related 
bone mineralization. This study aimed to determine the association of the plasma FGF23 
concentration with intracranial cerebral atherosclerosis (ICAS) and extracranial cerebral ath-
erosclerosis (ECAS).
Methods  We prospectively enrolled 262 first-ever ischemic stroke patients in whom brain 
magnetic resonance was performed and a blood sample acquired within 24 h after admis-
sion. Plasma FGF23 concentrations were measured using an enzyme-linked immunosorbent 
assay. The presence of ICAS or ECAS was defined as a ≥50% decrease in arterial diameter in 
magnetic resonance angiography. The burden of cerebral atherosclerosis was calculated by 
adding the total number of vessels defined as ICAS or ECAS.
Results  Our study population included 152 (58.0%) males. The mean age was 64.7 years, 
and the plasma FGF23 concentration was 347.5±549.6 pg/mL (mean±SD). ICAS only, ECAS 
only, and both ICAS and ECAS were present in 31.2% (n=82), 4.9% (n=13), and 6.8% (n=18) 
of the subjects, respectively. In multivariate binary and ordinal logistic analyses, after adjust-
ing for sex, age, and variables for which p<0.1 in the univariate analysis, the plasma FGF23 
concentration (per 100 pg/mL) was positively correlated with the presence of ICAS [odds ra-
tio (OR)=1.07, 95% CI=1.00–1.15, p=0.039], burden of ICAS (OR=1.09, 95% CI=1.04–1.15, 
p=0.001), and burden of ECAS (OR=1.06, 95% CI=1.00–1.12, p=0.038), but it was not signifi-
cantly related to the presence of ECAS (OR=1.05, 95% CI=0.99–1.12, p=0.073). 
Conclusions  The plasma FGF23 may be a potential biomarker for cerebral atherosclerosis, 
particularly the presence and burden of ICAS in stroke patients.
Key Words   fibroblast growth factor 23, Klotho, cerebral atherosclerosis, 
intracranial atherosclerosis.
Plasma Fibroblast Growth Factor 23 Concentration Is 
Associated with Intracranial Cerebral Atherosclerosis 
in Acute Ischemic Stroke Patients
INTRODUCTION
Intracranial cerebral atherosclerosis (ICAS) is a major risk factor for cerebrovascular dis-
ease, particularly in Asians. ICAS is also associated with recurrent stroke, stroke-related 
morbidity, and future mortality.1 The importance of ICAS for stroke patients and the as-
sociated factors and risk factors remain unclear, although they have been suggested to be 
aging, racial differences (mainly Asian), hypertension, diabetes mellitus, smoking, obstruc-
tive sleep apnea, and obesity.2-4 Thus, further evaluations to find the factors that explain 
ICAS are necessary.
Fibroblast growth factor 23 (FGF23) is an endocrine FGF and phosphaturic hormone 
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mainly formed by osteoblasts and osteocytes.5 In harmony 
with Klotho (a single-pass transmembrane protein expressed 
in renal tubules), as an obligate coreceptor to bind and acti-
vate FGF receptors, FGF23 is activated during bone miner-
alization and turnover defects.6 In addition, kidney dysfunc-
tion, adipose tissue inflammation, and vitamin D dysregulation 
are involved in systemic FGF23 regulation.7 FGF23 is also in-
volved in systemic atherosclerosis via nitric-oxide-associated 
endothelial dysfunction and calcium-phosphate-related bone 
mineralization.8 Previous studies have found increased FGF23 
to be associated with subclinical atherosclerosis and an in-
creased left ventricular mass.9-11 Furthermore, FGF23 is an 
independent predictor of cardiovascular events in the general 
population.12
Major features of ICAS include atherosis caused by choles-
terol deposition and inflammation and sclerosis secondary 
to endothelial dysfunction, leading to arterial stiffness.1 Be-
cause FGF23 is also involved in the development of athero-
sclerosis and endothelial dysfunction,9-11,13 this growth factor 
might also be associated with the atherosclerosis of intracra-
nial vessels. We hypothesized that a higher circulating FGF23 
concentration is associated with the presence and burden of 
cerebral atherosclerosis in patients with acute ischemic stroke.
METHODS
Subjects
We prospectively registered 262 patients with first-ever isch-
emic stroke who were admitted to our institution between 
June 2014 and May 2016 within 7 days after symptom onset 
and had a stroke subtype classified as large-artery atheroscle-
rosis, cardioembolism, or small-vessel occlusion. Standard 
protocols for the stroke registry were applied to all patients, 
which included a chest X-ray; 12-lead electrocardiography; 
routine blood tests at admission (white blood cell count, WBC) 
and creatinine) and after a 12-h fast {vitamin D [25(OH)D], 
fasting glucose, HbA1c, triglyceride, total cholesterol, low-
density lipoprotein, total calcium, phosphate, albumin, alka-
line phosphatase, uric acid, and CRP}; brain imaging with CT 
and/or MRI; and vascular imaging with CT angiography, 
magnetic resonance angiography (MRA), or digital subtrac-
tion angiography.14,15 Patients who did not agree to participate 
in the study, refused to provide blood samples, or who had a 
history of cancer, autoimmune disease, or bone fractures dur-
ing the previous 2 months were excluded.
Risk factors were defined as in a previous study and the 
Supplementary Materials (in the online-only Data Supple-
ment).16 The stroke subtype was classified using the Trial of 
Org 10172 in Acute Stroke Treatment (TOAST) classifica-
tion system.17 Briefly, patients with potential cardiac emboli 
were classified as the cardioembolic subtype. If a patient ex-
hibited substantial stenosis of the relevant artery, they were 
classified as the large-artery atherosclerosis subtype. The 
small-vessel occlusion subtype was defined if all of the follow-
ing criteria were met: clinical manifestation of classical lacu-
nar syndrome, relevant subcortical or brainstem lesion, infarc-
tion smaller than 15 mm, no significant stenosis in the relevant 
artery, and no potential cardiac embolism.18 The Fazekas scor-
ing system was used to assess white-matter hyperintensities 
(WMHs) in MRI FLAIR.19 A Fazekas score of ≥2 in the peri-
ventricular or deep white matter was defined as high-grade 
WMH. The renal function was investigated using the estimat-
ed glomerular filtration rate according to the Modification of 
Diet in Renal Disease study equation.20 This study was ap-
proved by our Institutional Review Board (approval no. ECT 
2014-04-023), and we obtained informed consent from all 
participants and their next of kin.
MRI protocol and definition of vascular stenosis
Every patient enrolled in this study underwent intracranial 
and extracranial MRA. All MR images were obtained using 
a 3.0-T imaging system (Magnetom Verio, Siemens Health-
care, Erlangen, Germany). Three-dimensional time-of-flight 
sequences were used to evaluate the intracranial arteries (in-
tracranial internal carotid artery, middle cerebral artery, an-
terior cerebral artery, posterior cerebral artery, distal vertebral 
artery, and basilar artery) and the extracranial arteries (extra-
cranial internal carotid artery and common carotid artery). 
Extracranial cerebral atherosclerosis (ECAS) was not assessed 
in the extracranial vertebral arteries because it is difficult to 
distinguish hypoplasia of the vertebral artery from significant 
stenosis.3 
The method used in this study to evaluate stenosis has 
been described previously,21 and >50% stenosis was defined 
as ICAS.22 ECAS was assessed using the criteria from the 
North American Symptomatic Carotid Endarterectomy Tri-
al, with its presence defined as >50% stenosis at the bifurca-
tion of the bilateral carotid artery.23 The most serious lesion 
was chosen when multiple stenotic lesions were present.22, 24 
The total number of vessels with ICAS was considered as the 
ICAS burden (ranging from 0 to 11), while the total number 
of vessels with ECAS was considered the ECAS burden (rang-
ing from 0 to 4).24 Two neurologists blinded to clinical infor-
mation (Y.C. and T.J.S.) independently assessed the pres-
ence of ICAS. The kappa value for interobserver agreement 
was 0.936 for the presence of ICAS. Any initial disagreements 
in the neurologist assessments of ICAS were resolved by 
discussion.
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Measurement of plasma FGF23 concentrations
To measure the plasma FGF23 concentration, a blood sample 
were collected after a 12-h fast in EDTA tubes. The blood was 
centrifuged at 1,900×g and 4°C for 15 min to obtain plasma, 
and then kept at -80°C until being analyzed. The plasma 
FGF23 concentrations were measured using an ELISA with a 
commercial reagent (Kainos Laboratories, Tokyo, Japan).25 
The concentration detection range was 3–800 pg/mL, and so 
the assay was repeated using a 1/10 dilution for concentrations 
>800 pg/mL.25 The plasma FGF23 concentration was mea-
sured twice by two investigators blinded to the medical data 
(Y.C. and D.R.R.) and then averaged. Intra- and interassay co-
efficients of variability were 4.2% and 6.5%, respectively.
Statistical analysis
Statistical analyses were conducted using the SPSS software 
package for Windows (version 21.0, IBM Corp., Armonk, NY, 
USA). Continuous variables were analyzed using the indepen-
dent t-test, Mann-Whitney test, one-way ANOVA with Bon-
ferroni’s post-hoc analysis, and Kruskal-Wallis test. Categor-
ical variables were analyzed using the chi-square or Fisher’s 
exact test. Univariate and multivariate binary logistic regres-
sion analyses were performed to investigate the association be-
tween the plasma FGF23 concentration and cerebral athero-
sclerosis. To investigate the associations of age, body mass in-
dex, stroke severity, time to blood sampling from symptom 
onset, and blood laboratory findings with FGF23, Spearman 
correlation analysis was performed for the correlations be-
tween the National Institutes of Health Stroke Scale (NIHSS) 
score, blood laboratory findings, and FGF23 concentration. 
The association between the plasma FGF23 concentra-
tion and the burden of cerebral atherosclerosis was investi-
gated by performing a Spearman correlation analysis and 
univariate and multivariate ordinal logistic regression anal-
yses. Ordinal logistic regression was used to analyze the as-
sociation between the FGF23 concentration and the number 
of arteries with cerebral atherosclerosis. The odds ratio (OR) 
in ordinal regression expresses the common odds for the in-
crease in the number of arteries with cerebral atherosclero-
sis at each count. Sex, age, and variables for which p<0.1 in 
the univariate analysis were included in the multivariate lo-
gistic regression. In the multivariate analysis, sex, age, body 
mass index, coronary artery disease, prestroke antithrombot-
ics, stroke subtype, NIHSS score, high-grade WMHs, Klotho, 
triglyceride, WBC count, total calcium, and C-reactive pro-
tein were adjusted for the presence and burden of ICAS; sex, 
age, hypertension, stroke subtype, NIHSS score, high-grade 
WMHs, WBC count, phosphate, and uric acid were adjusted 
for the presence and burden of ECAS; and sex, age, hyper-
tension, prestroke antithrombotics, NIHSS score, high-grade 
WMHs, Klotho, triglyceride, WBC count, and C-reactive pro-
tein were adjusted for the presence and burden of both ICAS 
and ECAS. For sensitivity analysis, we investigated the pres-
ence of statistical interactions according to underlying renal 
dysfunction (<60 mL/min/1.73 m2), which was closely relat-
ed to the plasma FGF23 concentration.11 A two-tailed proba-
bility value of p<0.05 was considered statistically significant.
RESULTS
Demographic data and comparative analysis 
according to presence of cerebral atherosclerosis
Fig. 1 shows a flowchart of participants according to the in-
clusion and exclusion criteria applied in this study. The de-
mographics and accompanying risk factors and prior stroke 
medications did not differ significantly between the includ-
ed and excluded patients (Supplementary Table 1 in the on-
line-only Data Supplement). Table 1 lists the demographics 
of the patients in our study. The 262 patients included 58.0% 
(n=152) males. The mean age was 64.7 years, and the plasma 
FGF23 concentration was 347.5±549.6 pg/mL (mean±SD). 
The most common stroke subtype was large-artery athero-
sclerosis (41.2%, n=108), followed by small-vessel occlusion 
(40.8%, n=107) and cardioembolism (17.9%, n=47). The plas-
ma FGF23 concentration did not differ among stroke sub-
types (p=0.174). ICAS only, ECAS only, and both ICAS and 
ECAS were present in 31.2% (n=82), 4.9% (n=13), and 6.8% 
(n=18) of the subjects, respectively (Table 1). The patients 
with ICAS and both ICAS and ECAS were older (p=0.002) 
Patients with 





Patient’s refusal for study 
enrollment 
(n=128)
Poor image quality 
(n=3)





Finally, 262 patients 
were enrolled
Fig. 1. Flowchart of participants according to inclusion and exclu-
sion criteria.
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and had higher NIHSS scores (p=0.002) than those without 
cerebral atherosclerosis. Moreover, patients with ICAS only, 
ECAS only, or both ICAS and ECAS more often had a histo-
ry of hypertension (p=0.003) and large-artery atherosclerosis 
stroke subtype (p=0.001). 
The blood laboratory findings indicated that the plasma 
FGF23 concentration (p=0.001), WBC count (p=0.014), and 
C-reactive protein concentration (p=0.017) were higher in 
patients with both ICAS and ECAS than in patients without 
cerebral atherosclerosis. Patients with ICAS had higher plasma 
concentrations of FGF23 (p=0.037) and C-reactive protein 
(p=0.043) compared with patients without cerebral athero-
sclerosis. Patients with both ICAS and ECAS had a higher plas-
ma FGF23 concentration compared with patients with only 
Table 1. Comparison of clinical characteristics and blood laboratory findings according the presence of cerebral atherosclerosis
Total 
(n=262)










Sex, male 152 (58.0) 89 (59.7) 10 (76.9) 43 (52.4) 10 (55.6) 0.365
Age, years 64.7±12.3 62.4±12.0 64.6±13.9 67.5±12.3* 71.5±8.5* 0.002
Body mass index, kg/m2 24.0±3.3 23.7±2.8 23.0±2.2 24.6±4.1 24.3±3.9 0.186
Risk factors
Hypertension 153 (58.4) 77 (51.7) 10 (76.9) 49 (59.8) 17 (94.4) 0.003
Diabetes mellitus 108 (41.2) 56 (37.6)   5 (38.5) 38 (46.3)   9 (50.0) 0.510
Hypercholesterolemia   74 (28.2) 40 (26.8)   2 (15.4) 27 (32.9)   5 (27.8) 0.553
Coronary artery disease   47 (17.9) 22 (14.8)   2 (15.4) 17 (20.7)   6 (33.3) 0.221
Smoking   98 (37.4) 56 (37.6)   5 (38.5) 31 (37.8)   6 (33.3) 0.986
Alcohol intake   73 (27.9) 48 (32.2)   4 (30.8) 17 (20.7)   4 (22.2) 0.282
Prior medication
Antithrombotics   55 (21.0) 24 (16.1)   2 (15.4) 21 (25.6)   8 (44.4) 0.024
Statins   53 (20.2) 32 (21.5)   4 (30.8) 13 (15.9)   4 (22.2) 0.561
Stroke subtype 0.001
Small-vessel occlusion 107 (40.8) 85 (57.0)   2 (15.4) 16 (19.5)   4 (22.2)
Large-artery atherosclerosis 108 (41.2) 37 (24.8)   9 (69.2) 51 (62.2) 11 (61.1)
Cardioembolism   47 (17.9) 27 (18.1)   2 (15.4) 15 (18.3)   3 (16.7)
NIHSS score 3 [2–6] 3 [2–5] 2 [1–8] 5 [2–8]* 6 [3–12]* 0.002
High-grade WMHs   64 (24.4) 30 (20.1)   4 (30.8) 22 (26.8) 8 (44.4) 0.115
Time to blood sampling from symptom onset, h 11.3 [4.6–20.4] 11.8 [5.0–21.1] 11.1 [4.1–19.8]11.0 [4.2–19.6] 11.2 [4.4–20.6] 0.218
Blood laboratory findings
FGF23, pg/mL 347.5±549.6 255.9±348.3 153.0±71.7 394.4±617.4* 1033.0±1073.1*†‡ 0.001
Klotho, pg/mL 312.7±153.3 327.0±140.4 382.1±253.4 285.1±142.2 270.1±190.8 0.045
Vitamin D [25(OH)D], ng/mL 20.1±6.8 19.9±7.0 17.9±6.6 21.1±6.7 19.7±5.4 0.350
HbA1c, % 6.5±1.4 6.4±1.3 6.9±1.7 6.7±1.5 6.4±1.1 0.224
Triglyceride, mg/dL 129.0±95.6 121.8±90.3 101.3±37.2 141.7±114.0 150.6±63.6 0.233
Low-density lipoprotein, mg/dL 115.0±36.9 112.2±35.4 111.6±49.7 118.5±37.9 124.6±33.9 0.401
White blood cell count, ×103 7.3±2.4 7.1±2.1 7.9±3.7 7.4±2.4 9.0±2.7* 0.014
Creatinine, mg/dL 1.0±0.8 1.0±0.9 0.9±0.1 0.9±0.3 1.3±1.5 0.182
Total calcium, mg/dL 8.2±0.4 8.2±0.4 8.2±0.4 8.3±0.4 8.3±0.6 0.375
Phosphate, mg/dL 3.1±0.6 3.1±0.5 3.3±0.6 3.1±0.5 3.5±1.0 0.083
Alkaline phosphatase, IU/L 224.4±72.2 225.1±70.4 209.0±45.1 227.8±81.6 213.7±58.0 0.761
Uric acid, mg/dL 4.8±1.6 4.8±1.5 5.5±1.9 4.6±1.5 5.2±2.1 0.288
CRP, mg/L 0.9±2.8 0.5±1.3 0.7±1.1 1.5±1.3* 2.2±3.2* 0.017
Data are n (%), mean±SD, or median [interquartile range] values.
*p<0.05 compared with no cerebral atherosclerosis in a Bonferroni post-hoc analysis, †p<0.05 compared with ECAS only in a Bonferroni post-hoc 
analysis, ‡p<0.05 compared with ICAS only in a Bonferroni post-hoc analysis.
ECAS: extracranial cerebral atherosclerosis, FGF23: fibroblast growth factor 23, ICAS: intracranial cerebral atherosclerosis, NIHSS: National Institute of 
Health Stroke Scale, WMHs: white-matter hyperintensities.
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ICAS (p=0.001) or only ECAS (p=0.001) (Table 1). 
The plasma FGF23 concentration was positively correlated 
with age (ρ=0.150, p=0.015), NIHSS score (ρ=0.198, p=0.001), 
vitamin D [25(OH)D] concentration (ρ=0.143, p=0.020), 
HbA1c (ρ=0.162, p=0.008), triglyceride concentration (ρ= 
0.319, p<0.001), WBC count (ρ=0.130, p=0.035), and creat-
inine (ρ=0.178, p=0.004), total calcium (ρ=0.153, p=0.043), 
phosphate (ρ=0.148, p=0.048), and C-reactive protein (ρ= 
0.134, p=0.030) concentrations. Moreover, the plasma FGF23 
concentration was negatively correlated with the Klotho con-
centration (ρ=-0.325, p<0.001). 
Association of FGF23 with presence of cerebral 
atherosclerosis
In a multivariate binary logistic analysis, the plasma FGF23 
concentration was positively correlated with the presence 
of ICAS even after adjustment as a continuous variable (per 
100 pg/mL) (OR=1.07, 95% CI=1.00–1.15, p=0.039) or di-
chotomizing based on the median value (cutoff value=182.0 
pg/mL; OR=2.52, 95% CI=1.36–4.68, p=0.003) and tertiles 
[comparing the upper tertile (≥235.16 pg/mL) with the lower 
tertile (0–146.79 pg/mL): OR=3.28, 95% CI=1.53–7.05] (Ta-
ble 2, Supplementary Table 2 in the online-only Data Supple-
ment). The plasma FGF23 concentration was marginally re-
lated to the presence of ECAS after adjustment as a continuous 
variable (per 100 pg/mL; OR=1.05, 95% CI=0.99–1.12, p= 
0.073), but it was not associated with the presence of ECAS 
after adjustment using the median cutoff value or tertiles 
(Table 2, Supplementary Table 2 in the online-only Data Sup-
plement). The plasma FGF23 concentration was significantly 
and positively correlated with the presence of both ICAS and 
ECAS after adjustment as a continuous variable (per 100 pg/
mL; OR=1.10, 95% CI=1.02–1.19, p=0.013) (Table 2, Sup-
plementary Table 2 in the online-only Data Supplement). 
There was no statistical interaction between the presence 
of ICAS (p for interaction=0.872) and ECAS (p for interac-
tion=0.764) with the presence of renal dysfunction (<60 
mL/min/1.73 m2).
Association of FGF23 with the burden of cerebral 
atherosclerosis
The plasma FGF23 concentration was associated with the 
ICAS burden (ρ=0.317, p=0.001) and the ECAS burden (ρ= 
0.145, p=0.019). The association of FGF23 with the burden 
of cerebral atherosclerosis is presented as Fig. 2. In a multi-
variate ordinal logistic analysis, the plasma FGF23 concentra-
tion was positively correlated with the burden of ICAS even 
after adjustment as a continuous variable (per 100 pg/mL; 
OR=1.09, 95% CI=1.04–1.15, p=0.001) or dichotomizing 
based on the median value (cutoff value=182.0 pg/mL; OR= 
1.10, 95% CI=1.58–5.06, p=0.001) and tertiles [comparing 
the upper tertile (≥235.16 pg/mL) with the lower tertile (0–
146.79 pg/mL): OR=3.30, 95% CI=1.60–6.75] (Table 2, Sup-
plementary Table 3 in the online-only Data Supplement). 
The plasma FGF23 concentration was related to the burden 
of ECAS after adjustment as a continuous variable (per 100 
pg/mL; OR=1.06, 95% CI=1.00–1.12, p=0.038) but not after 
adjustment using the median cutoff value or tertiles (Table 2, 
Supplementary Table 3 in the online-only Data Supplement). 
The plasma FGF23 concentration was significantly and pos-
itively correlated with the burden of both ICAS and ECAS 
after adjustment as a continuous variable (per 100 pg/mL; 
OR=1.10, 95% CI=1.02–1.19, p=0.013) (Table 2, Supplemen-
tary Table 3 in the online-only Data Supplement).
Fig. 2. Association of FGF23 with the burden of ICAS (A) and the burden of ECAS (B). X-axis indicates the burden of each type of cerebral athero-
sclerosis, and Y-axis indicates the value of natural logarithm of FGF23. ECAS: extracranial cerebral atherosclerosis, FGF23: fibroblast growth factor 
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DISCUSSION
The key finding of our study is that a higher plasma FGF23 
concentration was associated with the presence and burden 
of cerebral atherosclerosis, particularly for ICAS. An associ-
ation of FGF23 with cerebral atherosclerosis has rarely been 
reported. A community-based study found that a higher cir-
culating FGF23 concentration was associated with systemic 
atherosclerosis.26 Moreover, a higher FGF23 concentration 
was found to be a risk factor for chronic kidney diseases, es-
pecially in older, disabled, community-dwelling females.27 In 
patients with chronic kidney diseases, an elevated FGF23 con-
centration reportedly contributes directly to a higher rate of 
left ventricular hypertrophy28 and a higher coronary artery 
disease burden.29 Combined with previous research, the pres-
ent study is significant because it confirms the association 
between the plasma FGF23 concentration and the presence 
and burden of cerebral atherosclerosis, specifically in stroke 
patients.
While our study cannot suggest the exact mechanism link-
ing plasma FGF23 and cerebral atherosclerosis, there are 
plausible hypotheses. First, vascular inflammation of cere-
bral arteries may explain the relationship between FGF23 and 
cerebral atherosclerosis. Previous studies have found FGF23 
to be an important mediator of vessel inflammation that pre-
ceded arteriolosclerosis or arterial stiffness, which was the 
main cause of cerebral atherosclerosis development, partic-
ularly for ICAS.22,30 Moreover, FGF23 stimulates the hepatic 
secretion of the inflammatory markers IL-6 and C-reactive 
protein.30 C-reactive protein is a sensitive indicator of vascular 
inflammation and a marker of cerebral atherosclerosis.31 In 
line with these previous results, the present study found that 
the plasma FGF23 concentration was positively correlated 
with that of C-reactive protein, with the latter also being high-
er in patients with accompanying ICAS than in those with-
out cerebral atherosclerosis. Second, FGF23 is a phosphatu-
ric hormone produced mainly by osteoblasts and osteocytes, 
and is implicated in blood calcium and phosphate concen-
trations, the vitamin D pathway, and ectopic site mineraliza-
tion.5 Increased FGF23 activity disturbs the calcitriol-calcium/
phosphate regulation pathway, which may cause hypercalce-
mia and hyperphosphatemia, likely accounting for the asso-
ciation with ectopic site mineralization.32,33 Previous studies 
have demonstrated the serum calcium concentration to be 
positively correlated with the presence of ICAS; in contrast, 
the serum phosphate concentration was not associated with 
ICAS.34 Furthermore, the phosphate concentration was posi-
tively correlated with a greater prevalence of vascular calcifi-
cation, which is frequently associated with ECAS.35,36 Therefore, 
an FGF23-related calcium-phosphate regulation mechanism 
may affect the development of cerebral atherosclerosis. Ac-
tually, the present study found that the plasma FGF23 was 
positively correlated with serum calcium and phosphate con-
centrations, and also that the serum calcium and phosphate 
Table 2. Results of multivariate analyses of the presence and burden of cerebral atherosclerosis
FGF23
Presence of cerebral atherosclerosis
ICAS† p ECAS‡ p Both ECAS and ICAS§ p
Continuous variable, per 100 pg/mL  1.07 (1.00–1.15) 0.039 1.05 (0.99–1.12) 0.073 1.10 (1.02–1.19) 0.013
Dichotomized based on median value of 182.0 pg/mL 2.52 (1.36–4.68) 0.003 1.59 (0.66–3.87) 0.248 Not available*
Tertiles
Lower tertile, 0–146.79 pg/mL Reference Reference Reference
Middle tertile, 146.79–235.16 pg/mL 1.96 (0.93–4.12) 0.076 1.97 (0.64–6.08) 0.482 Not available*
Upper tertile, ≥235.16 pg/mL 3.28 (1.53–7.05) 0.002 1.26 (0.42–3.75) 0.523 Not available*
FGF23
Burden of cerebral atherosclerosis
ICAS† p ECAS‡ p Both ECAS and ICAS§ p
Continuous variable, per 100 pg/mL  1.09 (1.04–1.15) 0.001 1.06 (1.00–1.12) 0.038 1.10 (1.02–1.19) 0.013
Dichotomized based on median value of 182.0 pg/mL 1.10 (1.58–5.06) 0.001 1.63 (0.66–3.99) 0.283 Not available*
Tertiles
Lower tertile, 0–146.79 pg/mL Reference Reference Reference
Middle tertile, 146.79–235.16 pg/mL 2.27 (1.10–4.67) 0.001 1.35 (0.44–4.11) 0.590 Not available*
Upper tertile, ≥235.16 pg/mL 3.30 (1.60–6.75) 0.026 2.09 (0.66–6.53) 0.204 Not available*
Data are odds ratio (95% CI) values.
*Odds ratio could not be obtained because the FGF23 concentrations of patients with both ECAS and ICAS exceeded 182.0 pg/mL, †Adjusted for sex, 
age, BMI, coronary artery disease, prestroke antithrombotics, stroke subtype, NIHSS score, high-grade WMHs, Klotho, triglyceride, WBC count, total 
calcium, and CRP, ‡Adjusted for sex, age, hypertension, stroke subtype, NIHSS score, high-grade WMHs, WBC count, phosphate, and uric acid, §Adjust-
ed for sex, age, hypertension, prestroke antithrombotics, NIHSS score, high-grade WMHs, Klotho, triglyceride, WBC count, and CRP.
BMI: body mass index, ECAS: extracranial cerebral atherosclerosis, FGF23: fibroblast growth factor 23, ICAS: intracranial cerebral atherosclerosis, NI-
HSS: National Institutes of Health Stroke Scale, WBC: white blood cell, WMHs: white-matter hyperintensities.
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concentrations were related to the presence and burden of 
ICAS and ECAS, respectively. 
This study found that the presence and burden of ICAS 
were significantly associated with a higher FGF23 concen-
tration, whereas the presence and burden of ECAS were not, 
even though they were related in a univariate analysis. These 
results may have been due to the sample being too small to 
reveal a relationship between FGF23 and ECAS. Moreover, 
other confounding factors such as hypertension are more 
strongly associated with ECAS than with the FGF23 concen-
tration. In addition, arterial stiffness may be associated with 
ICAS (rather than ECAS) in Asians,22 and arterial stiffness is 
also closely related to FGF23,37 which may explain our results. 
Our study also suggests the presence of a pathophysiological 
association between circulating FGF23 and ICAS.
This study was subject to some limitations. We did not 
measure the plasma FGF23 concentration in the general pop-
ulation. However, the main goals of our study were to deter-
mine any associations with the presence and burden of cere-
bral atherosclerosis in stroke patients. All blood samples and 
brain imaging findings in this study were acquired from acute 
stroke patients at the time of admission, and so serial changes 
in the FGF23 concentration and the association of FGF23 
with the long-term progression of cerebral atherosclerosis 
could not be investigated. Although our study prospectively 
enrolled ischemic stroke patients, it is difficult to generalize 
our findings and selection bias might have been present due 
to the smallness of the sample and the exclusion of undeter-
mined stroke subtypes. Even though the plasma FGF23 con-
centration was found to be associated with the presence of 
ICAS and ECAS, it did not differ among stroke subtypes. 
This may have been due to the cardioembolic stroke mecha-
nism or the sample smallness reducing the statistical power. 
Finally, we did not measure thyroid and parathyroid hormones 
that may affect the FGF23 concentration, or examine bone 
abnormalities in the enrolled patients.
In conclusion, this study has demonstrated that a higher 
plasma FGF23 concentration is independently associated 
with the presence and burden of cerebral atherosclerosis, par-
ticularly with ICAS in stroke patients. We attribute these as-
sociations to the essential role of FGF23 in cerebral athero-
sclerosis.
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